Illumina last week filed a suit against Illumavista Biosciences, accusing the 3-year-old Madison, Wis.-based array firm of trademark infringement, unfair competition, and false designation or origin.

Illumina filed its suit on Nov. 27 in the US District for the Western District of Wisconsin. In it, Illumina alleges that the defendant is "deliberately and willfully" using the name Illumavista to "pass its SNAP microarray technology and bioinformatics data analysis services off as those of Illumina."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.